Pfizer, BioNTech confirm high efficacy of COVID-19 vaccine up to 6 months

By The Science Advisory Board staff writers

April 2, 2021 -- Pfizer-BioNTech's BNT162b2 COVID-19 vaccine is 91.3% effective against the virus six days through up to six months after the second dose, according to results from a phase III study where 927 participants exhibited signs of COVID-19. Participants were followed through March 13, 2021.

In the study, 927 patients contracted COVID-19, 850 were in the placebo group, and 77 were in the vaccine group, equating to a 91.3% efficacy rate. However, BNT162b2 is 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC). Using the U.S. Food and Drug Administration's (FDA) definition of severe COVID-19, the vaccine is 95.3% effective.

In terms of variants, in South Africa where the B.1.351 variant is prevalent, 800 participants were enrolled in the study and nine cases of COVID-19 were observed, all in the placebo group. This indicates the vaccine is 100% effective against the variant.

Regarding safety data, the vaccine demonstrates a favorable safety and tolerability profile as demonstrated in data collected from more than 12,000 vaccinated participants with a follow-up time of at least six months after the second dose.

The data paves the way for Pfizer and BioNTech to submit a biologics license application to the FDA, the firms said.

Pfizer-BioNTech's COVID-19 vaccine shows 100% effectiveness in adolescents
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine demonstrated 100% efficacy and robust antibody responses in people between the ages of 12 and 15, according...
Pfizer starts evaluation of SARS-CoV-2 oral antiviral
Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and...
Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine
Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully...
Pfizer, BioNTech study 3rd booster of vaccine to protect against variants
Pfizer and BioNTech have started to evaluate the safety and immunogenicity of a third dose of their COVID-19 vaccine BNT162b2 as a booster on immunity...
Pfizer, BioNTech vaccine neutralizes SARS-CoV-2 variants in vitro
Pfizer and BioNTech has released results from in vitro neutralization studies of blood sera from individuals vaccinated with its COVID-19 vaccine, providing...

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter